Ian S. Dayes

1280 Main Street West
Hamilton, ON L8S4L8, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Editorial expression of concern: Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways.

Editorial expression of concern: Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways.

Journal: Radiation oncology (London, England)

Published: July 06, 2026

Correction: Prospective study on 18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.

Correction: Prospective study on 18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.

Journal: British journal of cancer

Published: April 15, 2026

Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.

Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial.

Journal: European urology

Published: December 23, 2025

Radiation Oncology Follow-Up of Prostate Cancer Survivors Following Completion of Radiotherapy: A Population-Based Study.

Radiation Oncology Follow-Up of Prostate Cancer Survivors Following Completion of Radiotherapy: A Population-Based Study.

Journal: Current oncology (Toronto, Ont.)

Published: December 05, 2025

18F-FDG PET/CT of Oligometastatic Disease in Locally Advanced Breast Cancer: PETABC Trial Post Hoc Analysis.

18F-FDG PET/CT of Oligometastatic Disease in Locally Advanced Breast Cancer: PETABC Trial Post Hoc Analysis.

Journal: Radiology

Published: August 05, 2025

In Reply to Onal et al. Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.

In Reply to Onal et al. Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.

Journal: The Prostate

Published: June 09, 2025

Prospective study on 18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.

Prospective study on 18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.

Journal: British journal of cancer

Published: May 06, 2025

Prospective study on 18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.

Prospective study on 18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma.

Journal: British journal of cancer

Published: May 06, 2025

Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy.

Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy.

Journal: International journal of radiation oncology, biology, physics

Published: April 08, 2025

Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.

Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.

Journal: The Prostate

Published: February 11, 2025

Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer.

Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer.

Journal: European urology oncology

Published: February 06, 2025

Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.

Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 16, 2024

Showing 1-12 of 52

Last Updated: 09/26/2026